Ellorarxine, a groundbreaking drug compound developed by Nevrargenics, is showing remarkable promise in the treatment of Amyotrophic Lateral Sclerosis (ALS) and has recently received approval from the MHRA to advance to human trials. This news brings a glimmer of hope to the over 5,000 individuals
Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
In a significant development for global health preparedness, RedHill Biopharma Ltd. has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance opaganib, a promising treatment for Ebola virus disease (EBOV). This collaboration marks a crucial step in combating
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent
In a dynamic twist within the pharmaceutical industry, several companies are locked in a fierce race to develop the next generation of obesity drugs. As the battle heats up, each aims to outdo the other, with innovations that promise to revolutionize the way obesity is treated. This race isn't
Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, progressive muscle-wasting disease that significantly impacts patients' quality of life. Limited therapeutic options are available, with current treatments failing to address the underlying muscle weakness driving the disease's
